Thermo Fisher Scientific collaborates with OpenAI to leverage AI to accelerate scientific innovation.

Thermo Fisher Scientific (TMO.US) announced on Thursday a partnership with OpenAI to leverage the artificial intelligence (AI) technology of this tech startup supported by Microsoft Corporation (MSFT.US) to advance its scientific innovation processes. As part of the collaboration, the life sciences company based in Waltham, Massachusetts, will integrate OpenAI's application programming interface (API) into its core business operations, including product development, service delivery, and customer interactions. This partnership is expected to enhance efficiency in multiple operational areas of Thermo Fisher Scientific, including its Accelerator Drug Development solution and PPD clinical research business. The company stated, "This partnership will help accelerate drug development speed and success rates, assisting clients in delivering drugs to patients at lower costs and quicker speeds." CEO Marc Casper added, "Through our collaboration with OpenAI, we are further integrating AI into all levels of operations, products, and services. We are working together to create an ecosystem that accelerates scientific breakthroughs, creating tangible value for customers, patients, and society."